Brief: Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Blood-brain Barrier Penetration, Brain Transduction in NHPs
13/03/2024 12:14
March 13 (Reuters) - Sangamo Therapeutics Inc SGMO.O :
* SANGAMO THERAPEUTICS ANNOUNCES DATA FROM NOVEL PROPRIETARY
NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING
BLOOD-BRAIN BARRIER PENETRATION AND BRAIN TRANSDUCTION IN NHPS
* SANGAMO THERAPEUTICS: EXPECTS TO FILE UP TO THREE
NEUROLOGY
INVESTIGATIONAL NEW DRUG SUBMISSIONS AND/OR CLINICAL TRIAL
APPLICATIONS BY END OF 2025
Source text for Eikon: ID:nBw31XTJha
Further company coverage: SGMO.O
((Reuters.Briefs@thomsonreuters.com;))